Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences' global Phase 3 study of Masupirdine (SUVN-502) for Alzheimer's disease agitation received a positive DSMB safety review and interim analysis. The study will continue as planned without modifications, with 88% enrollment completed and top-line results expected in Q2 2027.
Jun 04 2026 10:54:11
Suven Life Sciences Ltd - 530239 - Clarification On Volume Movement Letter
Suven Life Sciences responded to a BSE query, stating there are no undisclosed material events affecting the stock's price or volume behavior. The company attributes recent movements to market speculation.
May 19 2026 12:46:53
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Suven Life Sciences announced the receipt of a Monitoring Agency Report from CRISIL Ratings. The report confirms that proceeds from the preferential issue have been fully utilized as per the disclosures for the quarter ended March 31, 2026, with no deviations found.
May 14 2026 12:43:54
Suven Life Sciences Ltd - 530239 - Board Meeting Outcome for Outcome Of Board Meeting Of Suven Life Sciences Limited Held On May 13, 2026
Suven Life Sciences Board approved FY26 consolidated financial results, reporting a net loss of ₹2,763.44 million and revenue of ₹210.45 million, up 19.89% YoY. The company also announced its 37th Annual General Meeting for August 25, 2026, and highlighted progress in its clinical pipeline, including 76% enrollment for SUVN-502 in Phase 3.
May 13 2026 13:55:24
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences has reached 76% enrollment in its global Phase 3 trial for Masupirdine (SUVN-502) aimed at treating Agitation in Alzheimer's Dementia. This milestone is a significant step in the clinical development towards a potential new treatment option.
May 12 2026 15:06:00
Read More